# Trulieve Cannabis share price today (Trulieve Cannabis Corp., TRLV)

> Trulieve Cannabis Corp.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TRLV · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/trlv

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $11.60 (+77.1% in a year)
- Revenue (Jun 2026): $271 M (−10.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −$406 M (one-off item, see below)
- Operating margin: 12.8% (−4.5 points on a year ago)
- ROE: −11%, FY25
- ROIC: 10.7%, against a 12.9% cost of capital: −2.2 points

Biggest thing to watch: the price has already been rising for 25 weeks, so timing is the risk more than the business. ## What is the Trulieve Cannabis share price today? Trulieve Cannabis Corp.'s share price was $11.60 at the close on 4 November 2026. It has been rising for 25 weeks. That is 30.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $5 and $12, and at that close it sat 91% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 9 weeks in a row. Over the last 8.1 years the share price moved −17% while the S&P 500 moved +166%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Trulieve Cannabis pay? Trulieve Cannabis Corp. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Trulieve Cannabis on? Trulieve Cannabis is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Trulieve Cannabis profitable? Trulieve Cannabis Corp. posted a net loss of $406 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $122 M. That loss is 149.9% of the quarter's revenue. The same quarter a year earlier lost $16.1 M. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −$406 M it is bigger than the quarter's whole revenue of $271 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a 12.8% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Trulieve Cannabis make, and is it growing? Trulieve Cannabis Corp. reported $271 M of revenue in the Jun 2026 quarter, −10.3% on the same quarter a year earlier. Over 4 years it has grown 6.1% a year on average. The last full year, FY25, came in at $1.2 B. The last four reported quarters add to $1.1 B. FY25 revenue was $1.2 B, −0.4% on the year before. Recent pace: the last four quarters grew −3.8% on average, against 6.1% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −3.9%, against −1.0% a year over the last 8 quarters (stabilising). ## How much of every $100 of sales does Trulieve Cannabis keep? Trulieve Cannabis Corp.'s operating margin was 12.8% in the Jun 2026 quarter, 4.5 percentage points lower than the same quarter a year ago. Across 5 years it has been between 7.8% and 28.6%. The latest quarter is within that range. Why the margin moved: operating margin changed −4.5 percentage points on the year while gross margin changed −0.7 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Trulieve Cannabis' profit turning into cash? Trulieve Cannabis Corp.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $273 M of operating cash against −$122 M of profit. After $44.2 M of spending on assets, $229 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Trulieve Cannabis' cash go? Trulieve Cannabis Corp. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $207 M on assets over the last 3 years. Averaged over those years that is 5.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $207 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Trulieve Cannabis' P/E ratio, and how does it compare with its own history? Trulieve Cannabis Corp. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Trulieve Cannabis Corp. at 1.9× its FY25 revenue of $1.2 B. The P/E comes back here once profit turns positive. ## Is the Trulieve Cannabis business getting better or worse? Trulieve Cannabis Corp.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Trulieve Cannabis earn on its capital? Trulieve Cannabis Corp. earned a ROE of −11% in FY25. That is up from a low of −38% in FY23. Its return on capital used (ROIC) is 2.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −10.3% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −10.3% net margin × 0.44× asset turnover × 2.36× leverage (assets divided by equity) ≈ −10.7% on equity. The margin does its share; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: 10.7% − 12.9% = −2.2 percentage points. The 12.9% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The 10.7% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −11.7%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Trulieve Cannabis have too much debt? Trulieve Cannabis Corp. has total debt of $578 M against shareholder equity of $766 M as of Jun 2026, so its debt is 0.75× its equity. Year by year, that ratio went from 0.39 in FY21 to 0.49 in FY25. Keep that borrowing in mind when reading the returns on this page. ## What is the Trulieve Cannabis shareholding pattern? 4.3% of Trulieve Cannabis Corp.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Trulieve Cannabis from balance-sheet trouble? For Trulieve Cannabis Corp., the Z-score is 0.78. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 0.78 is inside the danger zone, so the balance sheet is a real risk. ## How does Trulieve Cannabis rank in its industry? 50.8 out of 100, rank 12 of 28 in Drug Manufacturers - Specialty & Generic, with 64% of the evidence available. Trulieve Cannabis Corp. scores 50.8 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 12. Relative strength against the index is 27.6%, and revenue and profit growth are weak. The four parts add up to the total exactly: 14 + 8.1 + 11.3 + 17.4 = 50.8. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Trulieve Cannabis compared with? Trulieve Cannabis ranks 12 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 50.8 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.1/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 18.2/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 8.2/20 · Lead over its industry -5.3% · Lead over S&P 500 6.1% · 1 year 9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 26.1 + 18.2 + 13.8 + 8.2 = 66.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.8/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.3/20 · Lead over its industry -13.9% · Lead over S&P 500 -3.7% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.8 + 20.8 + 10.3 + 4.3 = 63.2 · What this means: Earnings are strong; relative strength in its sector is -13.9% and the one-year return is 15.8%. 3. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 62.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 12.2/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 16.8/20 · Lead over its industry 43.2% · Lead over S&P 500 59% · 1 year 150.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 24.1 + 12.2 + 9 + 16.8 = 62.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.9/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.8/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.5/20 · Lead over its industry 17.1% · Lead over S&P 500 30.9% · 1 year 25.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.9 + 12.8 + 10.9 + 18.5 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 60.0 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.1/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.8/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.4/20 · Lead over its industry 18.3% · Lead over S&P 500 31.8% · 1 year 40.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.1 + 11.8 + 8.7 + 18.4 = 60 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.4/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 15.3/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.1/20 · Lead over its industry -19.8% · Lead over S&P 500 -10.4% · 1 year -9.9% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.4 + 15.3 + 11.8 + 7.1 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 15.1/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 12.8/20 · Lead over its industry 11.3% · Lead over S&P 500 23.9% · 1 year 75.5% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21.4 + 15.1 + 9.3 + 12.8 = 58.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.6/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 3.6/20 · Lead over its industry -18% · Lead over S&P 500 -8.4% · 1 year 16.2% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.6 + 18.1 + 11 + 3.6 = 58.3 · What this means: Earnings are strong; relative strength in its sector is -18% and the one-year return is 16.2%. 9. [Liquidia Corporation](https://www.sectoralpha.in/us/stocks/lqda) LQDA · quiet · Evidence leans up · 64% evidence 55.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 100% · Profit n/a · Operating margin change 474.2 points · 62% evidence Capital efficiency 17.9/25 · ROCE 50.7% · Operating margin 49.8% · 76% evidence Valuation 9.2/20 · P/E 51.2× · PEG n/a · 15% evidence Relative strength 2.7/20 · Lead over its industry -19.6% · Lead over S&P 500 -10.2% · 1 year 81.6% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 17.9 + 9.2 + 2.7 = 55.8 · What this means: Earnings are strong; relative strength in its sector is -19.6% and the one-year return is 81.6%. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.5/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.3/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.4/20 · Lead over its industry -2.5% · Lead over S&P 500 8.9% · 1 year 35.5% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.5 + 20.3 + 9.2 + 11.4 = 55.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.4 out of 100 Growth Capital Valuation Relative
12. Trulieve Cannabis Corp. this page TRLV · breaking out · Evidence leans up · 64% evidence 50.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.0/35 · Revenue -3.9% · Profit n/a · Operating margin change -4.5 points · 62% evidence Capital efficiency 8.1/25 · ROCE 6.6% · Operating margin 12.8% · 76% evidence Valuation 11.3/20 · P/E -13.3× · PEG n/a · 15% evidence Relative strength 17.4/20 · Lead over its industry 14.6% · Lead over S&P 500 27.6% · 1 year 77.1% · 100% evidence · 11 of 12 weeks ahead Exact sum: 14 + 8.1 + 11.3 + 17.4 = 50.8 · What this means: Relative strength against the index is 27.6%, and revenue and profit growth are weak. 13. [Pacira BioSciences, Inc.](https://www.sectoralpha.in/us/stocks/pcrx) PCRX · breaking out · Evidence leans up · 64% evidence 50.3 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans down · 64% evidence 48.3 out of 100 Growth Capital Valuation Relative
15. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 47.1 out of 100 Growth Capital Valuation Relative
16. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 46.9 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · basing · Too little evidence to rank firmly · 56% evidence 46.2 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 44.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.8 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 40.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · basing · Evidence leans down · 71% evidence 37.8 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.7 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.4 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 47.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · losing its lead · Too little evidence to rank firmly · 47% evidence 30.6 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Trulieve Cannabis in size? Trulieve Cannabis is the 22nd largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Bausch Health Companies Inc., Prestige Consumer Healthcare Inc. and HUTCHMED (China). Just below it: Perrigo Company plc, BioCryst Pharmaceuticals, Inc. and Xeris Biopharma Holdings, Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) $3.1 billion
2. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) $2.5 billion
3. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) $2.4 billion
4. Trulieve Cannabis Corp. $2.2 billion
5. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) $2.2 billion
6. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) $2.1 billion
7. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) $1.9 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Pelagos Insurance Capital Limited](https://www.sectoralpha.in/us/stocks/plgo) $2.3 billion · Insurance - Diversified
2. [Septerna, Inc.](https://www.sectoralpha.in/us/stocks/sepn) $2.2 billion · Biotechnology
3. Trulieve Cannabis Corp. $2.2 billion
4. [Federal Agricultural Mortgage Corporation](https://www.sectoralpha.in/us/stocks/agm) $2.2 billion · Credit Services
5. [WaFd, Inc.](https://www.sectoralpha.in/us/stocks/wafd) $2.2 billion · Banks - Regional

## What else do people ask about Trulieve Cannabis? ### What were Trulieve Cannabis's latest quarterly results? Trulieve Cannabis Corp. reported revenue of $271 M and a net loss of $406 M for the Jun 2026 quarter. Earnings per share were −$2.11. The operating margin was 12.8%, 4.5 percentage points lower than a year earlier (as of 4 November 2026). ### What is Trulieve Cannabis's market cap? Trulieve Cannabis Corp.'s market capitalisation is $2.2 B at a stock price of $11.60. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Trulieve Cannabis performing? Trulieve Cannabis Corp.'s share price has been rising for 25 weeks. Over the past 13 weeks it has done better than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Trulieve Cannabis's stock price go up? This page does not forecast Trulieve Cannabis Corp.'s stock price. What it shows instead: the stock price is $11.60, and it has been rising for 25 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Trulieve Cannabis in its business cycle? Trulieve Cannabis Corp.'s FY25 operating margin was 12.6%, against a 5-year range of 7.8% to 28.6%: the low end of its own range, which is often where recoveries start. The latest quarter was 12.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Trulieve Cannabis story? Biggest thing to watch: the price has already been rising for 25 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Trulieve Cannabis a stock worth studying right now? What the numbers show: Trulieve Cannabis Corp.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.